AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.7k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2752 trials with phase data)• Click on a phase to view related trials
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
- Conditions
- Lung Neoplasms
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT07109154
- Locations
- 🇧🇷
Ensino e Terapia de Inovação Clinica AMO- ETICA, Salvador, Bahia, Brazil
🇧🇷Instituto D'oR de Pesquisa e Ensino, Recife, Pernambuco, Brazil
🇧🇷Oncoclínicas Rio de Janeiro S.A, Rio de Janeiro, Brazil
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT07109219
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap
- Conditions
- Renal Insufficiency, Chronic
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT07103629
- Locations
- 🇧🇷
Sociedade Brasileira de Nefrologia, São Paulo, Brazil
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3402
- Registration Number
- NCT07103642
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort
- Conditions
- Gynaecological Cancers
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT07101081
- Locations
- 🇧🇷
Oncoclínicas Precision Medicine, São Paulo, SP, Brazil
- Prev
- 1
- 2
- 3
- 4
- 5
- 662
- Next
News
SOPHiA GENETICS and AstraZeneca Expand AI Partnership to Optimize Breast Cancer Treatment Outcomes
SOPHiA GENETICS and AstraZeneca announced a multi-year collaboration expansion to leverage multimodal AI Factories for generating evidence on breast cancer therapy efficacy and real-world impact.
Symbiosis Pharmaceutical Services Achieves Manufacturing Milestone with 1,000th Sterile Injectable Batch
Symbiosis Pharmaceutical Services, a global contract manufacturing organization, has successfully completed its 1,000th sterile drug product batch since its founding in 2011.
Major Pharmaceutical Companies Lead Global Renal Failure Clinical Trials Landscape in 2025
A comprehensive 2025 clinical trials report reveals the global landscape of renal failure research, featuring data from over 80 clinical trial registries worldwide.
AstraZeneca and Revna Biosciences Launch Targeted EGFR Therapy for Lung Cancer Patients in Ghana
AstraZeneca has launched a targeted therapy for EGFR-mutated lung cancer patients in Ghana through its strategic partnership with Revna Biosciences, marking a significant milestone in expanding access to precision oncology in sub-Saharan Africa.
GSK's TIM-3 Inhibitor Cobolimab Fails Phase III Trial in Advanced Lung Cancer
GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.
Ionis Pharmaceuticals Reports Strong Q2 2025 Results, Raises Guidance on TRYNGOLZA Success
Ionis Pharmaceuticals delivered $19 million in net product sales for TRYNGOLZA in Q2 2025, driving a doubling of total revenue to $452 million compared to the same period last year.
AIM ImmunoTech Reports Promising Mid-Year Results from Phase 2 Pancreatic Cancer Combination Therapy Study
AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment.
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
STRIDE Immunotherapy Achieves Unprecedented 19.6% Five-Year Survival Rate in Advanced Liver Cancer
A new exploratory analysis of the HIMALAYA phase III trial shows that 19.6% of patients with unresectable hepatocellular carcinoma treated with STRIDE immunotherapy remained alive after five years, compared to 9.4% with sorafenib.
AstraZeneca Announces $50 Billion US Investment Plan with Virginia Manufacturing Hub for Weight Management and Metabolic Drugs
AstraZeneca announces a $50 billion investment in the United States by 2030, with Virginia selected as the site for the company's largest single manufacturing facility investment globally.